a Open Access Full Text Article

CORRIGENDUM Quantification of Synergistic Effects of Ceragenin CSA-131 Combined with Iron Oxide Magnetic Nanoparticles Against Cancer Cells [Corrigendum]

Piktel E, Markiewicz KH, Wilczewska AZ, et al. Int J Nanomedicine. 2020;15:4573-4589.

It has been brought to the authors attention that Figure 6E showing nanosystem-mediated DNA fragmentation in DLD-1 colorectal cancer cells is a duplicate of part of Figure 3C that was previously published in the review article: Wnorowska U, Fiedoruk K, Piktel E, et al. J Nanobiotechnology. 2020;18(1):3 (https://doi.org/10.1186/s12951-019-0566-z). In addition, both Figures 5E and 6E were described with incorrect treatment conditions. Data obtained during corresponding experiments were verified; consequently, Figure 5E and 6E were updated using data from the original study.

The correct Figure 5 is as follows.



Figure 5 Continued.

Received: 2 February 2023 Accepted: 2 February 2023 Published: 10 February 2023

CC 0 S C223 Piktel et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://ww work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).



Figure 5 Anticancer activity of ceragenin CSA-131 and ceragenin-containing nanoformulations against lung carcinoma A549 cells. Increase of intracellular levels of reduced thiols in A549 cells treated with CSA-131 (grey bar), MNP@CSA-131 (red bar), CSA-131+MNP (blue bar) and MNP (yellow bar) when compared to untreated control (0 μ g/mL; black bar) (**A**). The percentages of dead cells (black columns), PI-negative cells with low viability (dark grey columns) and healthy cells (light grey columns) in lung carcinoma cells treated with CSA-131, MNP@CSA-131, CSA-131 and MNP or naked MNPs (**B**). The proliferation of cancer cells treated with CSA-131 (grey squares), MNP@CSA-131 (red circles), CSA-131 + MNP (blue diamonds) and MNP (yellow inverted triangles) when compared to untreated control (black squares) estimated using reszurin-based fluorimetric method (**C**). Induction of apoptosis in A549 cells by CSA-131 and its magnetic derivatives (**D**). Percentage of early apoptotic (black columns), late apoptotic/dead cells (dark grey columns) and dead cells (light grey columns). For the purpose of the clarity of the presented data, live cells (Annexin V-negative and 7-AAD-negative) were not presented in the provided figures. Morphological alternations in nuclei of A549 cells upon treatment with CSA-131, MNP@CSA-131 and CSA-131 + MNP when compared to uncreated cells (**E**). White arrows indicate treatment-induced morphological changes in nuclei of treated cells. All experiments were performed using agents at a concentration of 10 μ g/mL for 24 h. (**A**–**D**) demonstrate results from 3 to 6 individual experiments ± SD, for panel E results from one representative experiment are shown. * and ^ indicate statistical significance (p-value <0.05) when comparing to control cells (0 μ g/mL) and CSA131-treated cells, respectively. Scale bar ~50 μ m.

The correct Figure 6 is as follows.



Figure 6 Continued.

Ε



Figure 6 Anti-cancer activity of ceragenin CSA-131 and ceragenin-containing nanoformulations against colon cancer DLD-1 cells. Increase of intracellular levels of reduced thiols in DLD-1 cells treated with CSA-131 (grey bar), MNP@CSA-131 (red bar), CSA-131+MNP (blue bar) and MNP (yellow bar) when compared to untreated control (0 μ g/mL; black bar) (**A**). The percentages of dead cells (black columns), PI-negative cells with low viability (dark grey columns) and healthy cells (light grey columns) in colon carcinoma cells treated with CSA-131, MNP@CSA-131, CSA-131 and MNP or naked MNPs (**B**). The proliferation of cancer cells treated with CSA-131 (red circles), CSA-131 + MNP (blue diamonds) and MNP (yellow inverted triangles) when compared to untreated control (black squares) estimated using resazurin-based fluorimetric method (**C**). Induction of apoptosis in DLD-1 cells by CSA-131 and its magnetic derivatives (**D**). Percentage of early apoptotic (black columns), late apoptotic/dead cells (dark grey columns) and dead cells (light grey columns). For the purpose of the clarity of the presented data, live cells (Annexin V-negative and 7-AAD-negative) were not presented in the provided figures. Morphological alternations in nuclei of DLD-1 cells upon treatment-induced morphological changes in nuclei of treated cells. All experiments were performed using agents at a concentration of 10 μ g/mL for 24 h. (**A**-**D**) demonstrate results from 3 to 6 individual experiments ± SD, for (**E**) results from one representative experiment are shown. * and ^ indicate statistical significance (p-value <0.05) when comparing to control cells (0 μ g/mL) and CSA131-treated cells, respectively. Scale bar ~50 μ m.

The authors sincerely apologize for these errors and guarantee that they do not impact the interpretation of the presented results and conclusions.

International Journal of Nanomedicine

Dovepress

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch[®], Current Contents[®]/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http:// www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/international-journal-of-nanomedicine-journal